Design to come?

WP_Post Object
(
    [ID] => 511
    [post_author] => 3
    [post_date] => 2020-09-17 14:09:58
    [post_date_gmt] => 2020-09-17 19:09:58
    [post_content] => 
    [post_title] => Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2020-10-07 14:12:56
    [post_modified_gmt] => 2020-10-07 19:12:56
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => http://vcapital.localhost/?post_type=news&p=511
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)